Figure 3.
![Comparison of rwOS after applying IPTW between patients with high-risk [presence of del(17p), del(11q), or unmutated IGHV] and non–high-risk CLL/SLL.](https://ash.silverchair-cdn.com/ash/content_public/journal/bloodadvances/9/15/10.1182_bloodadvances.2024015417/1/blooda_adv-2024-015417-gr3.jpeg?Expires=1756607961&Signature=XRRLTCeJ~b4hFAo0SXIH2JCnxE03Eo3QOiPk6k1XNoMg14sDfB41jN~pKgO6uz9iFvB886QwGEshCbfWeYRCQDJT2i6GO8YK2pzlcxwQni6BKkvG-b1TUwejCkw-Rs7CN1VImBMjVSqASfx~fl6wHVCRRJoOO85KT3-J0xRCIIgCAAX31bKZOMzsqsfwUl3nfQ~-FTJ~fh~I0VYq9seJxcvdY05E8qj08rrt02O671F4o1zhhOKIryPFeRDIOaAJGbBiQIutLP6hruRceYKNwmhXMOOzYOww3hlyXK4ZwvM5FxqX3FaLilgAdlqWQBmqexDL9d3Y3wFvoMgQAa0zkg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Comparison of rwOS after applying IPTW between patients with high-risk [presence of del(17p), del(11q), or unmutated IGHV] and non–high-risk CLL/SLL.
Comparison of rwOS after applying IPTW between patients with high-risk [presence of del(17p), del(11q), or unmutated IGHV] and non–high-risk CLL/SLL.
